Periprocedural, Short-Term, and Long-Term Outcomes of Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy: A 20-Year Single-Center Experience

ABSTRACT

Background: Alcohol septal ablation is recommended for hypertrophic obstructive cardiomyopathy patients who had refractory symptoms despite optimal medical treatment. We compared the periprocedural, short-, and long-term clinical outcomes and mortality predictors in hypertrophic obstructive cardiomyopathy patients who underwent alcohol septal ablation.

Methods: Hypertrophic obstructive cardiomyopathy patients aged ≥18 years (63 females and 71 males) who underwent alcohol septal ablation were included. The primary endpoint was all-cause mortality.

Results: The mean patient age was 60.0 (standard deviation 13.7) years. The median follow-up time was 13 (7.6-18.5) years. During the procedure, 9, 2, and 1 patients developed ventricular fibrillation, remote site myocardial infarction, and pericardial tamponade, respectively, but none died. One patient died during hospitalization. During the long-term follow-up, 17, 5, 20, and 8 patients developed heart failure, myocardial infarction, chronic atrial fibrillation, and non-fatal stroke, respectively, and 24 died. There was no significant difference between the sexes (all P > .05). Age (hazard ratio = 0.69, 95% CI = 0.61-0.78, P < .001), body mass index (hazard ratio = 1.20, 95% CI = 1.04-1.40, P = .01), age at diagnosis (hazard ratio = 1.57, 95% CI = 1.34-1.78, P < .001), and time from diagnosis to ablation (hazard ratio = 1.57, 95% CI = 1.35-1.84, P < .001) predicted all-cause mortality. In Kaplan–Meier curves, long-term all-cause mortality was similar in men and women (P[log-rank] = .43).

Conclusion: Alcohol septal ablation has similar short- and long-term outcomes for both sexes in hypertrophic obstructive cardiomyopathy patients. Risk factors for long-term mortality were age, body mass index, diagnosis age, and time delay to operation. Therefore, alcohol septal ablation timing is essential for better clinical outcomes. Our findings may contribute to the increased performance of alcohol septal ablation in hypertrophic obstructive cardiomyopathy patients in our country.

Keywords: Alcohol septal ablation, hypertrophic obstructive cardiomyopathy, outcomes, sex

INTRODUCTION

Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disease. In the absence of predisposing conditions, a left ventricular wall thickness of ≥15 mm indicates HCM. Approximately one-third of patients do not have left ventricular outflow tract (LVOT) obstruction. In the rest, LVOT obstruction causes symptoms, systolic anterior movement of the mitral valve, and changes in ventricular geometry. Additionally, systolic and diastolic dysfunction, myocardial ischemia, and atrial arrhythmias also contribute to patients’ symptoms.

Septal reduction therapy (alcohol septal ablation and surgical myectomy) is recommended in hypertrophic obstructive cardiomyopathy (HOCM) patients with refractory symptoms despite optimal medical treatment. Septal reduction decreases LVOT obstruction, mitral regurgitation, left atrial diameter, left ventricular filling pressure, pulmonary pressure. Although surgical myectomy was the first-choice treatment, the recommendations for alcohol septal ablation have changed. It was previously recommended only in patients with advanced...
age, high risk, or comorbidities. However, its indications have been expanded with reports of complication rates and long-term survival times being comparable with myectomy. It is indicated as an alternative to surgery in the current guidelines. However, there is no consensus regarding the choice between surgical myectomy and alcohol septal ablation.

Single-center and multicenter studies have shown the periprocedural, short-term, and long-term results of alcohol septal ablation in HOCM patients. However, no such study has been conducted in Turkey. Moreover, few studies have examined the differences in clinical outcomes of alcohol septal ablation in HOCM patients between the sexes. Therefore, this study aimed to determine and compare the periprocedural, short-term, and long-term clinical outcomes and mortality predictors in male and female HOCM patients who underwent alcohol septal ablation.

METHODS

Three hundred twenty-four HOCM patients were retrospectively evaluated based on medical records. Ethical approval was obtained from the Hospital Regional Ethics Committee (No. 2021-07-28, Date: April 5, 2021). All participants' rights were protected, and written informed consent was obtained before the procedures, according to the Helsinki Declaration of 2013.

The criteria for alcohol septal ablation were as follows: interventricular septal (IVS) thickness \( \geq 15 \) mm on echocardiography, maximal LVOT gradient \( \geq 30 \) mmHg or \( \geq 50 \) mmHg with provocative maneuvers, New York Heart Association (NYHA) class 3-4 dyspnea, or Canadian Cardiovascular Society class 3-4 angina, despite optimal medical treatment, and recurrent syncope episodes. Overall, 138 patients met the criteria for alcohol septal ablation. Four patients were excluded due to procedural failure. Thus, 134 HOCM patients aged \( \geq 18 \) years who underwent alcohol septal ablation between 2000 and 2020 at our institution were included in this retrospective cohort study. The patients were divided into female (n=63, 47%) and male (n=71, 53%) groups.

Procedural Technique

A transvenous temporary pacemaker was applied at the start of the procedure because of the total A-V block risk. Coronary artery disease was ruled out by diagnostic coronary angiography in suspected patients. Pressure gradients were recorded using catheters placed in the aorta and LVOT. Undiluted contrast agents were used for the septal artery injection.

The estimated target septal artery was wired using a double-curved soft floppy guidewire. An "over-the-wire" balloon was then advanced and inflated to avoid backflow of alcohol into the left anterior descending artery, thereby preventing infarction of remote myocardial areas. A single marker balloon was chosen for easier insertion of the balloon catheter into the septal artery. After the guidewire was withdrawn, a contrast agent was injected through the balloon catheter with simultaneous transthoracic echocardiography.

Selective angiography of the target septal branch through the inflated balloon catheter documented the adequate sealing of the septal branch. It excluded filling of any other coronary artery through the septal collaterals.

Up to 2-4.5 cm\(^3\) (1 cm\(^2\)/1 cm septal thickness) of absolute alcohol was injected slowly and continuously through the lumen of the balloon catheter under fluoroscopic, hemodynamic, and electrocardiographic monitoring. Ten minutes after the last alcohol injection, the balloon catheter was withdrawn. A final angiogram showed complete occlusion of the septal branch and normal flow in the left anterior descending artery. Measurements of the outflow tract pressure gradient at rest and with provocation were repeated. If LVOT gradients remained at \( >25 \) mm Hg, the same procedure was repeated for the other target septal artery.

Demographic data, cardiovascular history, echocardiographic findings, ECG and Holter findings, symptoms, and medications of all patients were obtained from the institutional database. Procedural results and complications were also recorded. Postprocedural LVOT gradients were evaluated at catheter laboratory discharge. The patients' septal thickness and NYHA class were assessed at the first-month follow-up visit.

The ICD selection criteria were as follows:

- History of sudden cardiac death and documented sustained ventricular tachycardia.
- History of sudden cardiac death in first-degree relatives under 50 years of age.
- Recurrent syncope episodes, suspected to be from arrhythmia.
- Patients with an apical aneurysm.
- Patients with scar rate >5% in cardiac MRI. The decision to implant a device was based on the relevant guidelines and the attending physician's discretion.

Outcomes

The primary endpoint of the study was all-cause mortality. Patients' follow-up visits were planned for 1 and 6 months, and then yearly, after the procedure. Long-term adverse event data were obtained at patient visits or telephonically. Patients with implanted cardioverter defibrillator devices (ICD-D) were evaluated for arrhythmic events. Cardiovascular mortality was defined as sudden cardiac
The most common symptom was dyspnea, followed by near-syncope/syncope. The frequencies of all symptoms were similar between the groups (all P > .05). The most common medication administered to HOCM patients was beta-blockers (76.9%). Patients on disopyramide and calcium channel blockers were 15.7% and 15.7%, respectively. The administration rates of calcium channel blocker, disopyramide, diuretic, angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, acetylsalicylic acid, and novel oral anticoagulant were similar in both the sexes (all P > .05).

Procedural Characteristics
Alcohol ablation was performed in 138 patients. The procedure was unsuccessful in 4 patients. The procedural characteristics and complications are summarized in Table 2. The mean alcohol consumption during the operation was not significantly different between the groups (P = .56). In 70.9% of the patients, a single septal branch contrast injection was performed under echocardiography guidance, and in 88% of the patients, a single septal branch alcohol injection was performed. The number of contrast- and alcohol-injected septal branches and maximal CK-MB levels after the procedure were similar between the 2 groups (all P > .05).

The major procedural complication rates were similar between the sexes (P = .06). During the procedure, 9 patients (6.7%) developed ventricular fibrillation (achieved sinus rhythm with defibrillation), 1 patient developed anterior MI, and 1 developed pericardial tamponade requiring pericardiocentesis. Only 2 patients (1.4%) had a permanent pacemaker. No mortality occurred during alcohol septal ablation (Table 2).

Thirty-one patients (23.1%) developed temporary total A–V block, and 7 patients (5.2%) developed pericardial effusion, which was minor complications.

During the hospital stay, 2 patients (1.4%) developed ventricular fibrillation (and achieved sinus rhythm with defibrillation), 2 patients (1.4%) developed acute heart failure and cardiogenic shock, 2 patients (1.4%) developed acute kidney disease, and 2 (1.4%) patients developed remote site acute MI; 1 patient (0.7%) died due to MI. All in-hospital complication rates were similar between the 2 groups (P = .05) (Table 2).

The mean LVOT maximal gradient on echocardiography at catheter laboratory discharge was not significantly different between the groups (P = .84). The mean IVS thickness decreased to 18 mm (range, 15–20 mm), and the NYHA 3–4 symptom rate dropped to 2.2% in the first-month post-procedure, without significant difference between the groups (P > .05; Table 2).

Implanted cardioverter defibrillator was successfully implanted in 22% of patients during hospitalization. There were no procedural complications.
### Table 1. Baseline Demographic Characteristics of the Alcohol Septal Ablation Patients

|                          | Total (n = 134) | Female, n = 63 (47%) | Male, n = 71 (53%) | P     |
|--------------------------|----------------|----------------------|--------------------|-------|
| Age, mean ± SD           | 60.0 (13.7)    | 63.4 (13.3)          | 56.9 (13.4)        | .006  |
| BMI, mean ± SD           | 26.1 (3.7)     | 26.4 (4.4)           | 25.9 (2.9)         | .450  |
| Diagnosis age, mean ± SD | 44.3 (12.7)    | 46.7 (12.9)          | 42.2 (12.2)        | .030  |
| Ablation age, mean ± SD  | 47.4 (13.8)    | 50.7 (14.2)          | 44.5 (12.8)        | .009  |
| Diagnosis to ablation (years), median (IQR) | 1.0 (0.16-4.2) | 1.0 (0.16-5.0) | 1.0 (0.16-5.0) | .170  |
| Prior ICD, n (%)         | 5 (3.7%)       | 1 (1.6%)             | 4 (5.6%)           | .370  |
| Prior pacemaker, n (%)   | 2 (1.5%)       | 0                    | 2 (2.8%)           | .490  |
| NYHA 3-4 (before ablation), n (%) | 78 (58.2%) | 42 (66.7%)          | 36 (50.7%)         | .060  |
| Dyspnea, n (%)           | 111 (82.8%)    | 54 (85.7%)           | 57 (80.3%)         | .400  |
| LVOT resting (mm Hg), median (IQR) | 80 (63-95) | 80 (58-95)          | 80 (65-96)         | .670  |
| LA (mm), mean ± SD       | 42.6 (4.6)     | 42.4 (4.7)           | 42.8 (4.5)         | .550  |
| IVS before ablation (mm), median (IQR) | 24 (21-26) | 24 (21-26)          | 24 (21-27)         | .670  |
| PW (mm), median (IQR)    | 13 (13-15)     | 13 (13-15)           | 14 (13-15)         | .070  |
| SAM, n (%)               | 96 (71.6%)     | 48 (76.2%)           | 48 (77.5%)         | .860  |
| Severe MR (3-4), n (%)   | 27 (20.1%)     | 11 (17.5%)           | 16 (22.5%)         | .460  |
| 0                        | 18 (13.4%)     | 7 (11.1%)            | 11 (15.5%)         | .460  |
| 1                        | 41 (30.6%)     | 16 (25.4%)           | 25 (35.2%)         | .290  |
| 2                        | 48 (35.8%)     | 29 (46.0%)           | 19 (26.8%)         | .270  |
| 3                        | 20 (14.9%)     | 9 (14.3%)            | 11 (15.5%)         | .270  |
| 4                        | 7 (5.2%)       | 2 (3.2%)             | 5 (7.0%)           | .130  |
| LVEDD (mm), median (IQR) | 42 (39-45) | 41 (39-44)          | 42 (40-47)         | .500  |
| LVESD (mm), median (IQR) | 26 (23-29) | 24 (22-29)          | 26 (23-30)         | .790  |
| EF, n (%)                | 64 (58-66)     | 64 (60-66)           | 64 (57-67)         | .560  |
| Beta-blocker, n (%)      | 103 (76.9%)    | 51 (81.0%)           | 52 (73.2%)         | .290  |
| Calcium channel blocker, n (%) | 21 (15.7%) | 12 (19.0%)          | 9 (12.7%)          | .310  |
| Diuretic, n (%)          | 15 (11.2%)     | 6 (9.5%)             | 9 (12.7%)          | .560  |
| Dysopiramid, n (%)       | 21 (15.7%)     | 12 (19.0%)           | 9 (12.7%)          | .310  |
| Amiodarone, n (%)        | 23 (17.2%)     | 11 (17.5%)           | 12 (16.9%)         | .930  |
| ACEI/ARB, n (%)          | 29 (21.6%)     | 14 (22.2%)           | 15 (21.1%)         | .870  |
| ASA, n (%)               | 24 (18.2%)     | 11 (17.5%)           | 13 (18.8%)         | .830  |
| NOAC, n (%)              | 27 (20.1%)     | 17 (27.0%)           | 10 (14.1%)         | .600  |

BMI, body mass index; ICD, implantable cardioverter-defibrillator; HOCM, hypertrophic obstructive cardiomyopathy; SCD, sudden cardiac death; NYHA, Newyork Heart Association; AF, atrial fibrillation; CAD, coronary artery disease; HT, hypertension; RBBB, right bundle branch block; LBBB, left bundle branch block; VT, ventricular tachycardia; LA, left atrium; LVOT, left ventricle outflow tract; IVS, interventricular septum; PW, posterior wall; LVEDD, left ventricle end-diastolic dimension; LVESD, left ventricle end-systolic dimension; EF, ejection fraction; SAM, systolic anterior movement; MR, mitral regurgitation; ACEI/ARB, angiotensin receptor inhibitor/angiotensin receptor blocker; ASA, acetylsalicylic acid; NOAC, novel oral anticoagulant; SD, standard deviation.
Long-Term Clinical Outcomes
The median follow-up duration was 13 (7.6-18.5) years. Seventeen (12.7%) patients developed CHF, 5 patients (3.7%) developed MI, 20 patients (14.9%) developed chronic AF, and 8 patients (6%) developed non-fatal stroke during follow-up. There was no significant difference in these complications between the groups (all \( P > .05 \)). Only 2 patients (1.55%) underwent re-ablation. Fifteen patients (11.3%) received an ICD-D, 3 patients (2.2%) received a pacemaker, and 8 patients underwent coronary revascularization. The need for ICD-D implantation was found to be significantly higher in female patients (\( P = .006 \)), while other intervention rates were similar in both sexes (\( P > .05 \)). Two patients (1.5%) underwent myectomy, and 1 (0.7%) patient underwent mitral valve replacement.

During a mean follow-up of 13 years, 24 patients died. Twelve of these patients (9.0%) had cardiovascular mortality. Seven patients (5.2%) suffered SCD, and 2 patients (1.5%) died of stroke, 2 (1.5%) of heart failure, and 1 patient (0.7%) of MI. Twelve patients (9%) had non-cardiac-related mortality. Four patients died of cancer, 2 of kidney failure, 2 of respiratory failure, 2 of pneumonia, and 2 of sepsis. Cardiovascular and all-cause mortality rates were similar in both groups (\( P = .84 \) and \( P = .43 \), respectively).

Mortality Predictors
The predictors of all-cause mortality were assessed using Cox regression analysis. Only BMI, age at diagnosis, and time from diagnosis to ablation time were significant according to the univariate analysis (\( P = .005 \), \( P = .001 \), and \( P = .006 \), respectively).

Table 2. Periprocedural, In-Hospital, and Long-Term Outcomes of the Patients

|                              | Total (n = 134) | Female, n = 63 (47%) | Male, n = 71 (53%) | P     |
|------------------------------|----------------|----------------------|-------------------|-------|
| Alcohol (cm³), median (IQR)  | 3.0 (2.5-3.5)  | 3.0 (2.5-3.5)        | 3.0 (2.5-3.5)     | .560  |
| Contrast injected branch, n (%) |                |                      |                   |       |
| 1                            | 95 (70.9%)     | 45 (71.4%)           | 50 (70.4%)        | .740  |
| 2                            | 36 (26.9%)     | 16 (25.4%)           | 20 (28.2%)        |       |
| 3                            | 1 (0.7%)       | 1 (1.6%)             | 0                 |       |
| 4                            | 2 (1.5%)       | 1 (1.6%)             | 1 (1.4%)          |       |
| Alcohol injected branch, n (%) |                |                      |                   |       |
| 1                            | 118 (88.1%)    | 57 (90.5%)           | 61 (85.9%)        | .530  |
| 2                            | 15 (11.2%)     | 6 (9.5%)             | 9 (12.7%)         |       |
| 3                            | 1 (0.7%)       | 0                    | 1 (1.4%)          |       |
| Peak CK-MB (mg/dL), median (IQR) | 212 (171-279) | 206 (150-255)        | 225 (180-298)     | .200  |
| Major procedural complications, n (%) | 16 (11.9%)    | 11 (17.5%)           | 5 (7.0%)          | .060  |
| All in-hospital complications, n (%) | 21 (15.7%)    | 14 (22.4%)           | 7 (9.9%)          | .050  |
| LVOT-max-after ablation (mm Hg), median (IQR) | 21 (10-32) | 21 (10-33) | 21 (11-32) | .840 |
| IVS (1 month), median (IQR)  | 18 (15-20)     | 18 (16-209)          | 17 (15-21)        | .660  |
| NYHA 3-4 (after 1 month), n (%) | 3 (2.2%)       | 2 (3.2%)             | 1 (1.4%)          |       |
| 1                            | 75 (56.0%)     | 29 (46.0%)           | 46 (64.8%)        |       |
| 2                            | 56 (41.8%)     | 32 (50.8%)           | 24 (33.8%)        |       |
| 3                            | 3 (2.2%)       | 2 (3.2%)             | 1 (1.4%)          |       |
| Long-term follow-up          |                |                      |                   |       |
| Follow-up (years), median (IQR) | 13.0 (7.6-18.5)| 14.0 (8.0-18.0)     | 12.0 (7.0-19.0)   | .920  |
| CHF, n (%)                   | 17 (12.7%)     | 10 (15.9%)           | 7 (9.9%)          | .290  |
| MI, n (%)                    | 5 (3.7%)       | 1 (1.6%)             | 4 (5.6%)          | .370  |
| Coronary revascularization, n (%) | 8 (6.0%)       | 3 (4.8%)             | 5 (7.0%)          | .720  |
| Chronic AF, n (%)            | 20 (14.9%)     | 11 (17.5%)           | 9 (12.7%)         | .430  |
| ICD, n (%)                   | 15 (11.3%)     | 12 (19.4%)           | 3 (4.2%)          | .006  |
| Pace-maker n (%)             | 3 (2.2%)       | 1 (1.6%)             | 2 (2.8%)          | 1.000 |
| Myectomy, n (%)              | 2 (1.5%)       | 0                    | 2 (2.8%)          | .490  |
| Re-ablation, n (%)           | 2 (1.55%)      | 2 (3.2%)             | 0                 | .210  |
| MVR, n (%)                   | 1 (0.7%)       | 1 (1.6%)             | 0                 | .470  |
| Nonfatal stroke, n (%)       | 8 (6.0%)       | 4 (6.3%)             | 4 (5.6%)          | 1.000 |
| Cardiovascular mortality, n (%) | 12 (9.0%)     | 6 (9.5%)             | 6 (8.6%)          | .840  |
| All-cause mortality, n (%)   | 24 (17.9%)     | 13 (20.6%)           | 11 (15.5%)        | .430  |

CK-MB, creatine kinase muscle brain; LVOT, left ventricle outflow tract; IVS, interventricular septum; NYHA, New York Heart Association; CHF, congestive heart failure; MI, myocardial infarction; AF, atrial fibrillation; ICD, implantable cardioverter-defibrillator; MVR, mitral valve replacement.
These factors were included in the multivariate analysis.

Age [hazard ratio (HR) 0.69, 95% CI 0.61-0.78, \( P < .001 \)], BMI (HR 1.20, 95% CI 1.04-1.40, \( P = .01 \)), age at diagnosis (HR 1.57, 95% CI 1.34-1.78, \( P < .001 \)), and time from diagnosis to ablation (HR 1.57, 95% CI 1.35-1.84, \( P < .001 \)) were found to be predictors of long-term all-cause mortality in HOCM patients who underwent alcohol septal ablation (Table 3). Sex, IVS thickness, and the NYHA class before the procedure were not predictors of long-term cardiac mortality (\( P = .30 \), \( P = .72 \), and \( P = .72 \), respectively). The Kaplan–Meier curves revealed that long-term all-cause mortality was similar in both men and women (\( P[\text{log-rank}] = .43 \) (Figure 1).

The mean survival time was 17.9 ± 0.8 (95% CI: 16.3-19.4) years for females and 18.6 ± 0.6 (95% CI: 17.6-20.08) years for male patients. The overall estimated survival time was 18.3 ± 0.5 (95% CI: 17.3-19.3) years.

Survival analyses showed an estimated 5-year survival rate of 91% (95% CI: 80-96%), the 10-year survival rate of 85% (95% CI: 73-92%), and a 20-year survival rate of 72% (95% CI: 56-83%) in female patients and an estimated 5-year survival rate of 93% (95% CI: 81-98%), the 10-year survival rate of 89% (95% CI: 78-95%), and 20-year survival rate of 72% (95% CI: 50-85%) in male patients (Figure 2).

**DISCUSSION**

This study showed that periprocedural, short-, and long-term outcomes in Turkish HOCM patients were similar in both sexes. Age, BMI, age at diagnosis, and time from diagnosis to ablation were predictors of long-term all-cause mortality. To the best of our knowledge, no previous study had such a long follow-up period or as many HOCM patients who underwent alcohol septal ablation in Turkey. Previous studies involved fewer patients and had shorter follow-up periods.15, 16

Because the patient’s chronological age at the time of study inclusion, the age at which the diagnosis was established, and the age at which the procedure was performed differed significantly (in years), we defined these separately. The higher the age and the time delay between the diagnosis and procedure, the greater was the mortality.

Female patients were older, and the age at diagnosis and ablation was higher in females than in males in our study. These findings are compatible with other studies.13, 14 The most common symptom of patients was dyspnea, similar to other studies.4,17

Calcium blocker and disopyramide usage rates seem low; however, they are similar to large septal ablation series.4,6 Disopyramide was used only in patients with refractory symptoms despite beta-blocker therapy. Furthermore, it is not available in our country. Lower rates of calcium channel

**Table 3. Cox Proportional Hazard Regression Analysis for All-Cause Mortality**

|               | Univariable |           |       | Multivariable |           |       |
|---------------|-------------|-----------|-------|---------------|-----------|-------|
|               | HR | 95% CI  | \( P \) | HR | 95% CI  | \( P \) |
| Age           | 1.02 | 0.99-1.05 | .110 | 0.69 | 0.61-0.78 | <.001 |
| Sex           | 0.72 | 0.32-1.63 | .440 | 1.74 | 0.62-4.9 | .290 |
| BMI           | 1.14 | 1.04-1.26 | .005 | 1.20 | 1.04-1.40 | .010 |
| Diagnosis age | 1.06 | 1.02-1.11 | .001 | 1.57 | 1.34-1.78 | <.001 |
| Diagnosis to ablation | 1.10 | 1.03-1.17 | .001 | 1.57 | 1.35-1.84 | <.001 |
| Septum thickness (before) | 1.006 | 0.91-1.11 | .900 | 0.97 | 0.85-1.11 | .720 |
| NYHA class (before) | 1.65 | 0.68-4.00 | 1.19 | 0.46-3.06 | .720 |
| Family SCD    | 0.52 | 1.23-2.22 | .380 |
| ICD           | 0.48 | 0.11-2.07 | .320 |
| Syncope       | 0.58 | 0.24-1.42 | .230 |
| Holter VT     | 0.87 | 0.29-2.55 | .800 |
| Holter AF     | 1.10 | 0.43-2.78 | .830 |
| LVOT max discharge | 1.01 | 0.99-1.03 | .100 |
| SAM           | 2.12 | 0.78-5.74 | .130 |
| EF %          | 0.97 | 0.91-1.03 | .350 |
| ICD           | 0.35 | 0.04-2.66 | .310 |
| Coroner revascularization | 0.04 | 0.00-94.76 | .420 |
| Beta-blocker  | 0.80 | 0.33-1.93 | .620 |
| Amiodarone    | 1.71 | 0.67-4.31 | .250 |

HR, hazard ratio; BMI, body mass index; ICD, implantable cardioverter–defibrillator; SCD, sudden cardiac death; NYHA, New York Heart Association; AF, atrial fibrillation; VT, ventricular tachycardia; LVOT, left ventricle outflow tract; EF, ejection fraction; SAM, systolic anterior movement.
blockers may be due to patients' intolerability because of bradycardia.

As expected, there was a significant improvement in the NYHA functional capacity of the patients from the first month after the procedure. The IVS thickness and LVOT gradient decreased, and symptomatic improvement continued during the long-term follow-up. Our cohort's baseline ECG, Holter, and echocardiographic characteristics were similar to those in other studies.9-11, 18 In most patients, echocardiography-guided contrast injection and alcohol injection into the first septal artery were sufficient to ensure procedural success, with results consistent with those of similar previous studies.4, 9, 11, 18 However, the mean amount of alcohol injected in our study patients was slightly higher than that in other single-center cohorts.19,20 The Euro-ASA registry concluded that a higher amount of alcohol was more effective in reducing LVOT gradient, with a concomitantly higher risk of total A-V block.21 Veselka et al22 showed that long-term mortality rates were similar to smaller (1-1.98 mL) and larger (2-3.8 mL) amounts of alcohol in a recent study. Moreover, a smaller amount of alcohol was associated with a higher rate of repeated ablations.22 It is plausible that serious arrhythmic complications would be rarer due to the prophylactic pacemaker implantation in all patients and the relatively lower mean age at ablation in our patients; thus, more significant amounts of alcohol were used in this study. Nevertheless, our center has decreased mean alcohol dose during septal ablation in recent years.

Although acute procedural complications occurred in approximately one-third of patients, only 12% of them were major complications. Moreover, there was no mortality during the procedure, and only 1 patient died during hospitalization. These low mortality rates are likely due to the operator's experience, catheter laboratory, intensive care team, and a coordinated multidisciplinary approach. In addition, these low mortality rates were consistent with those in other studies.4, 13, 18, 23

Although the rate of permanent pacemakers appears to be low (2.2%) in our study cohort, the rate of ICD implantation must be added to the pacemaker ratio (11.3%) as it includes the pacemaker function.

The frequency of ICD application was significantly higher in female patients, which may be due to several reasons. Some studies have shown that the long-term prognosis of female patients is worse in the course of HOCM.12, 13 It is known that the frequency of ICD implantation is higher. Women were older at diagnosis, which increases the risk of ventricular arrhythmia and sudden death in these patients.

The predictors of long-term mortality in HOCM patients differed between the studies. Consistent with several studies, age, ablation age, and BMI were predictors of long-term mortality in our study.13, 18 In addition, we also examined the effect of the time between HOCM diagnosis and ablation on long-term mortality and found a significant impact. While age at ablation, septal thickness, and LVOT gradient were predictors of mortality in the Euro-ASA registry, baseline EF, baseline NYHA class, number of alcohol-injected septal branches, beta-blocker usage, and number of ablations were predictors of all-cause mortality in the North American registry.8, 21 Sorajja et al24 found that patients aged ≥65 years with a septal thickness of <18 mm and a left anterior descending artery diameter of <4 mm had better 4-year symptoms and survival rates. Veselka et al25 found that excessive septal thickness (≥30 mm) was associated with cardiac mortality. Contrary to these studies, female, NYHA class, septal thickness, and LVOT gradient at catheter discharge did not predict all-cause mortality in our study. These differences may be due to cohort characteristics, operator and clinical experience, alcohol dose, and follow-up duration. Suppose the number of patients in our study was more extensive. In that case, septal thickness, SAM, NYHA class, etc., which were not significant in the univariate analysis but had significant HR, could be predictors of mortality. In addition, the endpoint of our study was
all-cause mortality, not cardiac mortality, which may affect the regression analysis’s mortality predictors.

In a recently published meta-analysis involving 4547 patients from 20 studies, the efficacy of alcohol septal ablation and myectomy in HOCM patients were compared. No significant difference was found between the groups in terms of all-cause death, cardiac death, and SCD. Additionally, Nguyen et al. showed no difference between the survival of HOCM patients after myectomy or alcohol septal ablation. With the recently updated guidelines, alcohol septal ablation has become the first choice in treating HOCM patients with severe symptoms resistant to medical treatment.5

Limitations of Study
This study has several limitations, including its single-center and retrospective design and relatively small sample size. Moreover, cardiac MRI and late echocardiographic findings were not included in the analysis because these data were incomplete. Some of the patients who underwent septal ablation were diagnosed in our center, and a few were referred from another institution. This may cause a gap in the data regarding age at diagnosis and time to ablation. However, these shortcomings were, to some extent, offset by the long follow-up duration of the study.

CONCLUSION
Alcohol septal ablation has similar short- and long-term outcomes for both sexes in HOCM patients. The risk factors for long-term all-cause mortality were age, BMI, diagnosis age, and time delay to operation. Therefore, alcohol septal ablation timing is essential for ensuring better outcomes. Our findings may contribute to the increased performance of alcohol septal ablation in HOCM patients in our country. More extensive, multicenter studies are required to confirm our findings.

Ethics Committee Approval: Ethical approval was obtained from the İstanbul Bakırköy Dr. Sadi Konuk Training and Research Hospital Regional Ethics Committee (No. 2021-07-28, Date: April 5, 2021).

Informed Consent: Written informed consent was obtained from all participants who participated in this study.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept — U.K.; Design — U.K., D.K.; Supervision — U.K., D.K.; Funding — D.K.; Materials — YY.C.; Data Collection and/or Processing — E.D.; Analysis and/or Interpretation — U.K., K.K.; Literature Review — U.K., YY.C., K.K.; Writing — U.K., K.K.; Critical Review — U.K., K.K., T.O.

Acknowledgments: None.

Declaration of Interests: None declared.

Funding: None.

REFERENCES
1. Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249-1254. [CrossRef]
2. Geske JB, Ommen SR, Gersh BJ. Hypertrophic cardiomyopathy: clinical update. JACC Heart Fail. 2018;6(5):364-375. [CrossRef]
3. Patel P, Dhillon A, Popovic ZB, et al. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy patients without severe septal hypertrophy: implications of the mitral valve and papillary muscle abnormalities assessed using cardiac magnetic resonance and echocardiography. Circ Cardiovasc Imaging. 2015;8(7):e003132. [CrossRef]
4. Batzner A, Pfeiffer B, Neugebauer A, Aicha D, Blank C, Seggewiss H. Survival after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2018;72(24):3087-3094. [CrossRef]
5. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients With hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association joint Committee on clinical practice guidelines. J Am Coll Cardiol. 2020;76(25):e159–e240. [CrossRef]
6. Kimmelstiel C, Zisa DC, Kuttab JS, et al. Guideline-based referral for septal reduction therapy in obstructive hypertrophic cardiomyopathy is associated with excellent clinical outcomes. Circ Cardiovasc Interv. 2019;12(7):e007673. [CrossRef]
7. Osman M, Kheiri B, Osman K, et al. Alcohol septal ablation vs. myectomy for symptomatic hypertrophic obstructive cardiomyopathy: systematic review and meta-analysis. Clin Cardiol. 2019;42(1):190–197. [CrossRef]
8. Nagueh SF, Groves BM, Schwartz L, et al. Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy: a multicenter North American registry. J Am Coll Cardiol. 2011;58(22):2322–2328. [CrossRef]
9. Sorousja P, Ommen SR, Holmes DR Jr, et al. Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2012;126(20):2374–2380. [CrossRef]
10. Veselka J, Krejčí J, Tomašov P, Zemánek D. Long-term survival after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a comparison with the general population. Eur Heart J. 2014;35(30):2040–2045. [CrossRef]
11. Jensen MK, Almasaas VM, Jacobsson L, et al. Long-term outcome of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: a Scandinavian multicenter study. Circ Cardiovasc Interv. 2011;4(3):256–265. [CrossRef]
12. Geske JB, Ong KC, Siontis KC, et al. Women with hypertrophic cardiomyopathy have worse survival. Eur Heart J. 2017;38(46):3434–3440. [CrossRef]
13. Wang Y, Wang J, Zou Y, et al. Female sex is associated with worse prognosis in patients with hypertrophic cardiomyopathy in China. PLoS ONE. 2014;9(7):e102969. [CrossRef]
14. Olivotto I, Maron MS, Adabag AS, et al. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46(3):480–487. [CrossRef]
15. Yavuzgil O, Tuluce K, Şimşek E, Gürgün C, Kültürsay H, Payzin S. Septal alcohol ablation in hypertrophic obstructive cardiomyopathy: a retrospective analysis. Turk Gogus Kalp Dama. 2012;20(3):427–433. [CrossRef]
16. Okay T, Dincer H, Moğolkoç M, et al. Occlusion of the septal artery in patients with hypertrophic obstructive cardiomyopathy: early and midterm results. Arch Turk Soc Cardiol. 2000;28:94–100.
17. An SY, Yang YJ, Hang F, Wang Z, Fan C. Procedural complication and long term outcomes after alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: data from China. Sci Rep. 2017;7:9506. [CrossRef]
18. Liebregts M, Faber L, Jensen MK, et al. Outcomes of alcohol septal ablation in younger patients with obstructive hypertrophic cardiomyopathy. JACC Cardiovasc Interv. 2017;10(11):1134–1143. [CrossRef]
19. Fortunato de Cano S, Nicolas Cano M, de Ribamar Costa J, et al. Long-term clinical follow-up of patients undergoing percutaneous alcohol septal reduction for symptomatic obstructive hypertrophic cardiomyopathy. Catheter Cardiovasc Interv. 2016;88(6):953-960. [CrossRef]

20. Nogic J, Koh Y, Bak M, Gooley RP, Meredith IT, McCormick LM. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a 16-year Australian single center experience. Heart Lung Circ. 2018;27(12):1446-1453. [CrossRef]

21. Veselka J, Jensen MK, Liebregts M, et al. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry. Eur Heart J. 2016;37(19):1517-1523. [CrossRef]

22. Veselka J, Faber L, Liebregts M, et al. Alcohol dose in septal ablation for hypertrophic obstructive cardiomyopathy. Int J Cardiol. 2021;333:127-132. [CrossRef]

23. Steggerda RC, Damman K, Balt JC, Liebregts M, ten Berg JM, van den Berg MP. Periprocedural complications and long-term outcome after alcohol septal ablation versus surgical myectomy in hypertrophic obstructive cardiomyopathy: a single-center experience. JACC Cardiovasc Interv. 2014;7(11):1227-1234. [CrossRef]

24. Sorajja P, Binder J, Nishimura RA, et al. Predictors of an optimal clinical outcome with alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Catheter Cardiovasc Interv. 2013;81(1):E58-E67. [CrossRef]

25. Veselka J, Jensen M, Liebregts M, et al. Alcohol septal ablation in patients with severe septal hypertrophy. Heart. 2020;106(6):462-466. [CrossRef]

26. Bytyci I, Nistri S, Mörner S, Henein MY. Alcohol Septal ablation versus septal myectomy treatment of obstructive hypertrophic cardiomyopathy: a systematic review and meta-analysis. J Clin Med. 2020;9(10):3062. [CrossRef]

27. Nguyen A, Schaff HV, Hang D, et al. Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy: a propensity score-matched cohort. J Thorac Cardiovasc Surg. 2019;157(1):306-315.e3. [CrossRef]